Table 2 Treatments received by patients at first line of therapy following diagnosis of metastatic disease, showing the percentage of patients in each modality of therapy
Treatment at 1st LoT | N | % of modality |
|---|---|---|
Endocrine (including targeted) | 139 | 100 |
Letrozole | 56 | 40.3 |
Anastrozole | 35 | 25.2 |
Exemestane | 23 | 16.5 |
Tamoxifen | 12 | 8.6 |
Everolimus + exemestane | 12 | 8.6 |
Other | < 6 | |
Chemotherapy | 46 | 100 |
Paclitaxel | 16 | 34.8 |
Epirubicin + cyclophosphamide | 14 | 30.4 |
Capecitabine | 7 | 15.2 |
Carboplatin + paclitaxel | 6 | 13 |
Other | < 6 |